Correlation Between Ocuphire Pharma and Pieris Pharmaceuticals
Can any of the company-specific risk be diversified away by investing in both Ocuphire Pharma and Pieris Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Ocuphire Pharma and Pieris Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Ocuphire Pharma and Pieris Pharmaceuticals, you can compare the effects of market volatilities on Ocuphire Pharma and Pieris Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Ocuphire Pharma with a short position of Pieris Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Ocuphire Pharma and Pieris Pharmaceuticals.
Diversification Opportunities for Ocuphire Pharma and Pieris Pharmaceuticals
0.66 | Correlation Coefficient |
Poor diversification
The 3 months correlation between Ocuphire and Pieris is 0.66. Overlapping area represents the amount of risk that can be diversified away by holding Ocuphire Pharma and Pieris Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Pieris Pharmaceuticals and Ocuphire Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Ocuphire Pharma are associated (or correlated) with Pieris Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Pieris Pharmaceuticals has no effect on the direction of Ocuphire Pharma i.e., Ocuphire Pharma and Pieris Pharmaceuticals go up and down completely randomly.
Pair Corralation between Ocuphire Pharma and Pieris Pharmaceuticals
Given the investment horizon of 90 days Ocuphire Pharma is expected to generate 1.92 times more return on investment than Pieris Pharmaceuticals. However, Ocuphire Pharma is 1.92 times more volatile than Pieris Pharmaceuticals. It trades about -0.02 of its potential returns per unit of risk. Pieris Pharmaceuticals is currently generating about -0.04 per unit of risk. If you would invest 119.00 in Ocuphire Pharma on September 3, 2024 and sell it today you would lose (6.00) from holding Ocuphire Pharma or give up 5.04% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Significant |
Accuracy | 60.94% |
Values | Daily Returns |
Ocuphire Pharma vs. Pieris Pharmaceuticals
Performance |
Timeline |
Ocuphire Pharma |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Pieris Pharmaceuticals |
Ocuphire Pharma and Pieris Pharmaceuticals Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Ocuphire Pharma and Pieris Pharmaceuticals
The main advantage of trading using opposite Ocuphire Pharma and Pieris Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Ocuphire Pharma position performs unexpectedly, Pieris Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pieris Pharmaceuticals will offset losses from the drop in Pieris Pharmaceuticals' long position.Ocuphire Pharma vs. Reviva Pharmaceuticals Holdings | Ocuphire Pharma vs. Protalix Biotherapeutics | Ocuphire Pharma vs. Eyepoint Pharmaceuticals | Ocuphire Pharma vs. Sellas Life Sciences |
Pieris Pharmaceuticals vs. Adaptimmune Therapeutics Plc | Pieris Pharmaceuticals vs. Mereo BioPharma Group | Pieris Pharmaceuticals vs. PDS Biotechnology Corp | Pieris Pharmaceuticals vs. Leap Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Other Complementary Tools
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |